# bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung
Canonical URL: https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-reports-first-quarter-2026-results-and-expanding-adoption-and-clinical-usage-of-cypathr-lung
Ticker: BIAF
Company: bioAffinity Technologies, Inc.
Source: bioAffinity Technologies, Inc.
Published: 2026-05-08 12:30 EST
Original Source URL: https://ir.bioaffinitytech.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-06-02 12:00 EST — [Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar](https://biopharmsignal.com/news/BIAF/multidisciplinary-physician-panel-to-share-real-world-benefits-of-bioaffinity-technologies-noninvasive-cypath-lung-cancer-test-in-upcoming-society-for-advanced-bronchoscopy-webinar) — Source: bioAffinity Technologies, Inc.
- 2026-05-27 12:00 EST — [bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology](https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-announces-notification-of-mexico-patent-allowance-covering-novel-lung-cancer-detection-methods-using-cypathr-lung-technology) — Source: bioAffinity Technologies, Inc.
- 2026-05-12 13:15 EST — [bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026](https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-reports-record-monthly-cypathr-lung-unit-sales-and-significant-year-over-year-growth-in-april-2026) — Source: bioAffinity Technologies, Inc.
- 2026-05-08 12:30 EST — [bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung](https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-reports-first-quarter-2026-results-and-expanding-adoption-and-clinical-usage-of-cypathr-lung) — Source: bioAffinity Technologies, Inc.
- 2026-04-28 13:16 EST — [bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment](https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-launches-new-study-to-expand-use-of-cypathr-lung-technology-for-asthma-and-copd-diagnosis-and-treatment) — Source: bioAffinity Technologies, Inc.
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)